Although a high number of recently developed multi-target-directed anti-AD drug candidates have included the active moiety of approved AChE inhibitor drugs (e.g., tacrine, donepezil), only a very few have enclosed the pharmacophoric moiety of the drug inhibitor of both ChEs (rivastigmine) [33,40,41]. The gene discussed is ACHE; the disease is Alzheimer disease.